A new IARC live webinar on evidence in primary cancer prevention By Ogkologos - November 11, 2021 498 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO TAT Honorary Award Recipient Announced Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC MOST POPULAR How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric... July 5, 2023 Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in... November 29, 2024 Load more HOT NEWS 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... More Than One in 10 Patients With Lung Cancer Do Not... Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival
